Sofinnova Partners closes Crossover II fund at €725 million, above target
Sofinnova Partners announced on November 16 the final close of its Sofinnova Crossover II fund at €725 million ($815 million), above its target, according to HedgeCo.Net. The Paris-, London- and Milan-based life sciences venture firm said the fund will back late-stage European life sciences companies.
Why “Unverified”
- Reported by HedgeCo.Net alone, with no second source or primary confirmation yet
1 independent source group across 1 post · evidence score 40/100. How labels work
What the sources claim
-
Sofinnova Partners announced the final close of Sofinnova Crossover II at €725 million.
“announced on November 16 the final close of Sofinnova Crossover II at €725 million”
HedgeCo.Net -
The fund closed above its target.
“Closed Its Crossover II Fund at €725 Million, Above Target”
HedgeCo.Net -
The fund is aimed at backing late-stage European life sciences companies.
“to Back Late-Stage European Life Sciences Companies”
HedgeCo.Net
Sources
More in ETFs & Funds
Embed this page
Summary and claims extracted by AI with prompt analyze-story@5 on 2026-11-16 12:00 UTC. Labels are computed from the sources, not by the model.